Literature DB >> 24965280

Factors associated with ordering laboratory monitoring of high-risk medications.

Shira H Fischer1, Jennifer Tjia, George Reed, Daniel Peterson, Jerry H Gurwitz, Terry S Field.   

Abstract

BACKGROUND: Knowledge about factors associated with provider ordering of appropriate testing is limited.
OBJECTIVE: To determine physician factors associated with ordering recommended laboratory monitoring tests for high-risk medications.
METHODS: Retrospective cohort study of patients prescribed a high-risk medication requiring laboratory monitoring in a large multispecialty group practice between 1 January 2008 and 31 December 2008. Analyses are based on administrative claims and electronic medical records. The outcome is a physician order for each recommended laboratory test for each prescribed medication. Key predictor variables are physician characteristics, including age, gender, specialty training, years since completing training, and prescribing volume. Additional variables are patient characteristics such as age, gender, comorbidity burden, whether the medication requiring monitoring is new or chronic, and drug-test characteristics such as inclusion in black box warnings. We used multivariable logistic regression, accounting for clustering of drugs within patients and patients within providers.
RESULTS: Physician orders for laboratory testing varied across drug-test pairs and ranged from 9% (Primidone-Phenobarbital level) to 97% (Azathioprine-CBC), with half of the drug-test pairs in the 85-91% ordered range. Test ordering was associated with higher provider prescribing volume for study drugs and specialist status (primary care providers were less likely to order tests than specialists). Patients with higher comorbidity burden and older patients were more likely to have appropriate tests ordered. Drug-test combinations with black box warnings were more likely to have tests ordered.
CONCLUSIONS: Interventions to improve laboratory monitoring should focus on areas with the greatest potential for improvement: providers with lower frequencies of prescribing medications with monitoring recommendations and those prescribing these medications for healthier and younger patients; patients with less interaction with the health care system are at particular risk of not having tests ordered. Black box warnings were associated with higher ordering rates and may be a tool to increase appropriate test ordering.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24965280      PMCID: PMC4242891          DOI: 10.1007/s11606-014-2907-9

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  44 in total

1.  The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review.

Authors:  G Worrall; P Chaulk; D Freake
Journal:  CMAJ       Date:  1997-06-15       Impact factor: 8.262

2.  Development and pilot testing of guidelines to monitor high-risk medications in the ambulatory setting.

Authors:  Jennifer Tjia; Terry S Field; Lawrence D Garber; Jennifer L Donovan; Abir O Kanaan; Marsha A Raebel; Yanfang Zhao; Jacquelyne C Fuller; Shawn J Gagne; Shira H Fischer; Jerry H Gurwitz
Journal:  Am J Manag Care       Date:  2010-07       Impact factor: 2.229

3.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.

Authors:  R A Deyo; D C Cherkin; M A Ciol
Journal:  J Clin Epidemiol       Date:  1992-06       Impact factor: 6.437

4.  Black box warning contraindicated comedications: concordance among three major drug interaction screening programs.

Authors:  Lorraine M Wang; Maple Wong; James M Lightwood; Christine M Cheng
Journal:  Ann Pharmacother       Date:  2009-12-29       Impact factor: 3.154

5.  Evolution of the surgeon-volume, patient-outcome relationship.

Authors:  Leon D Boudourakis; Tracy S Wang; Sanziana A Roman; Rani Desai; Julie A Sosa
Journal:  Ann Surg       Date:  2009-07       Impact factor: 12.969

6.  Doctors' perceptions of laboratory monitoring in office practice.

Authors:  Roberta E Goldman; Christine S Soran; Geoffrey L Hayward; Steven R Simon
Journal:  J Eval Clin Pract       Date:  2010-12       Impact factor: 2.431

7.  Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.

Authors:  Matthijs van Luin; Ferdinand W Wit; Colette Smit; Irma M Rigter; Eric J F Franssen; Clemens Richter; Frank Kroon; Frank de Wolf; David M Burger
Journal:  Ther Drug Monit       Date:  2011-02       Impact factor: 3.681

8.  Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents.

Authors:  Dan W Haupt; Lisa C Rosenblatt; Edward Kim; Ross A Baker; Richard Whitehead; John W Newcomer
Journal:  Am J Psychiatry       Date:  2009-01-15       Impact factor: 18.112

9.  Comparison of different comorbidity measures for use with administrative data in predicting short- and long-term mortality.

Authors:  Yu-Tseng Chu; Yee-Yung Ng; Shiao-Chi Wu
Journal:  BMC Health Serv Res       Date:  2010-05-27       Impact factor: 2.655

Review 10.  Compliance with dosing guidelines in patients with chronic kidney disease.

Authors:  Charron L Long; Marsha A Raebel; David W Price; David J Magid
Journal:  Ann Pharmacother       Date:  2004-03-30       Impact factor: 3.154

View more
  3 in total

1.  Laboratory monitoring for pharmaceuticals: familiarity does not breed contempt.

Authors:  Cynthia A Jackevicius; Peter Glassman
Journal:  J Gen Intern Med       Date:  2014-12       Impact factor: 5.128

Review 2.  What methods are being used to create an evidence base on the use of laboratory tests to monitor long-term conditions in primary care? A scoping review.

Authors:  Martha M C Elwenspoek; Lauren J Scott; Katharine Alsop; Rita Patel; Jessica C Watson; Ed Mann; Penny Whiting
Journal:  Fam Pract       Date:  2020-11-28       Impact factor: 2.267

3.  Characteristics and management of patients with inflammatory bowel disease between a secondary and tertiary hospitals: a propensity score analysis.

Authors:  Ki Hwan Song; Eun Soo Kim; Yoo Jin Lee; Byung Ik Jang; Kyeong Ok Kim; Sang Gyu Kwak; Hyun Seok Lee
Journal:  Intest Res       Date:  2018-04-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.